Table 3 Prognostic factors of progression free survival and overall survival
From: Biomarkers of resistance to radiation therapy: a prospective study in cervical carcinoma
| Â | Progression-free survival | Overall survival | ||||||
|---|---|---|---|---|---|---|---|---|
Univariate Cox model | Multivariate Cox Model | Univariate Cox model | Multivariate Cox Model | |||||
Variables | HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI |
FIGO | ||||||||
IIB | 1.00 | Â | Â | Â | 1.00 | Â | Â | Â |
IIIB | 1.22 | 0.72–2.07 | 1.03 | 0.57–1.88 | 2.03 | 0.87–4.73 | 1.69 | 0.64–4.53 |
Differentiation degree | ||||||||
Well | 1.00 | Â | Â | Â | 1.00 | Â | Â | Â |
Moderately | 2.35 | 0.72–7.69 | 2.89 | 0.85–9.86 | 1.65 | 0.38–7.05 | 2.42 | 0.56–10.5 |
Poorly | 1.78 | 0.45–7.03 | 1.83 | 0.46–7.50 | 0.92 | 0.15–0.56 | 0.95 | 0.15–5.70 |
Treatment type | ||||||||
Exclusive EBRT + Brachytherapy | 1.00 | Â | Â | Â | 1.00 | Â | Â | Â |
Chemo-Radiotherapy + Brachytherapy | 0.58 | 0.35–0.95 | 0.57 | 0.32–1.00 | 0.38 | 0.18–0.80 | 0.36 | 0.16–0.82 |
Tumor protein strong expression | ||||||||
SURVIVIN | 1.02 | 0.46–2.28 | 1.37 | 0.51–3.67 | 1.35 | 0.40–4.47 | 1.80 | 0.51–6.46 |
IGF1R-β | 1.53 | 0.81–2.89 | 1.81 | 0.87–3.76 | 2.7 | 0.94–7.73 | 5.38 | 1.59–18.3 |
IGF1R-α | 1.07 | 0.57–1.98 | 1.08 | 0.54–2.17 | 1.58 | 0.60–4.12 | 2.06 | 0.70–6.12 |
GLUT-1 | 0.99 | 0.54–1.83 | 1.04 | 0.55–1.98 | 1.66 | 0.77–3.55 | 2.22 | 0.99–5.04 |
HIF-1α | 1.46 | 0.79–2.70 | 1.56 | 0.80–3.05 | 0.92 | 0.42–2.00 | 0.94 | 0.41–2.17 |
CAIX | 0.52 | 0.20–1.32 | 0.50 | 0.20–0.30 | 0.53 | 0.16–1.77 | 0.58 | 0.17–2.02 |
Impact of anemia | ||||||||
Hb | 2.20 | 1.33–3.65 | 1.78 | 1.00–3.15 | 2.11 | 1.04–4.33 | 2.01 | 0.92–4.40 |